143 related articles for article (PubMed ID: 37410014)
1. Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding.
Alqahtani A; Alhousari D; Ali A; Yaghmour G; Orgel E; Curran E; Stock W; Bhojwani D; Alachkar H
Expert Opin Drug Metab Toxicol; 2023; 19(6):357-366. PubMed ID: 37410014
[TBL] [Abstract][Full Text] [Related]
2. Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.
Wu S; Wang M; Alqahtani A; Lou M; Stock W; Bhojwani D; Alachkar H
Biomed Pharmacother; 2022 Jun; 150():113000. PubMed ID: 35658244
[TBL] [Abstract][Full Text] [Related]
3. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
4. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Hijiya N; van der Sluis IM
Leuk Lymphoma; 2016; 57(4):748-57. PubMed ID: 26457414
[TBL] [Abstract][Full Text] [Related]
5. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
Lau KM; Saunders IM; Goodman A
J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
[TBL] [Abstract][Full Text] [Related]
6. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Earl M
Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
[TBL] [Abstract][Full Text] [Related]
7. Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia
.
Thu Huynh V; Bergeron S
Clin J Oncol Nurs; 2017 Oct; 21(5):E248-E259. PubMed ID: 28945721
[TBL] [Abstract][Full Text] [Related]
8. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
Burke PW; Hoelzer D; Park JH; Schmiegelow K; Douer D
ESMO Open; 2020 Oct; 5(5):e000858. PubMed ID: 33037033
[TBL] [Abstract][Full Text] [Related]
9. SOHO State of the Art Updates and Next Questions | Asparaginase-Understanding and Overcoming Toxicities in Adults with ALL.
Aldoss I; Pourhassan H; Douer D
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):787-794. PubMed ID: 36114134
[TBL] [Abstract][Full Text] [Related]
10. An experience with plasma exchange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to L-asparaginase.
Bilgir O; Calan M; Bilgir F; Cagliyan G; Arslan O
Transfus Apher Sci; 2013 Oct; 49(2):328-30. PubMed ID: 23871581
[TBL] [Abstract][Full Text] [Related]
11. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
12. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
Schulte R; Hinson A; Huynh V; Breese EH; Pierro J; Rotz S; Mixon BA; McNeer JL; Burke MJ; Orgel E
Cancer Med; 2021 Nov; 10(21):7551-7560. PubMed ID: 34528411
[TBL] [Abstract][Full Text] [Related]
13. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
Alachkar H; Fulton N; Sanford B; Malnassy G; Mutonga M; Larson RA; Bloomfield CD; Marcucci G; Nakamura Y; Stock W
Pharmacogenomics J; 2017 Jun; 17(3):274-279. PubMed ID: 27019981
[TBL] [Abstract][Full Text] [Related]
14. SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
Schmiegelow K; Rank CU; Stock W; Dworkin E; van der Sluis I
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):725-733. PubMed ID: 34511319
[TBL] [Abstract][Full Text] [Related]
15. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
16. [Successful readministration of L-asparaginase after development of severe hypertriglyceridemia in a young adult with T-cell acute lymphoblastic leukemia].
Watanabe K; Yoshifuji K; Ohkawa R; Tozuka M; Miura O; Arai A
Rinsho Ketsueki; 2018; 59(12):2555-2560. PubMed ID: 30626788
[TBL] [Abstract][Full Text] [Related]
17. Management of hypertriglyceridemia in children with acute lymphoblastic leukemia under persistent therapy with glucocorticoids and L-asparaginase during induction chemotherapy.
Salvador C; Meister B; Crazzolara R; Kropshofer G
Pediatr Blood Cancer; 2012 Oct; 59(4):771. PubMed ID: 22619026
[No Abstract] [Full Text] [Related]
18. Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.
Finch ER; Smith CA; Yang W; Liu Y; Kornegay NM; Panetta JC; Crews KR; Molinelli AR; Cheng C; Pei D; Ramsey LB; Karol SE; Inaba H; Sandlund JT; Metzger M; Evans WE; Jeha S; Pui CH; Relling MV
Pediatr Blood Cancer; 2020 Jan; 67(1):e28040. PubMed ID: 31612640
[TBL] [Abstract][Full Text] [Related]
19. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
[TBL] [Abstract][Full Text] [Related]
20. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Bade NA; Lu C; Patzke CL; Baer MR; Duong VH; Law JY; Lee ST; Sausville EA; Zimrin AB; Duffy AP; Lawson J; Emadi A
J Oncol Pharm Pract; 2020 Jan; 26(1):74-92. PubMed ID: 30917738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
